Ftse Mib
34.249,77
0,91%
DAX
18.161,01
1,32%
S&P 500
5.099,96
1,02%
NASDAQ Composite
15.927,90
2,03%
Bitcoin
62.940,68
-1,25%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Assistenza
Home Investire Azioni U.S.A. NYSE Qiagen NV (QGEN) Qiagen NV (QGEN) Notizie

Qiagen NV

QGEN
41,65
0,57 (1,39%)
27 Apr 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NYSE
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
24/4/202422:05GLOBEQIAGEN expands tuberculosis portfolio with new NGS Panel to..
09/4/202415:48GLOBEQIAGEN N.V. to release results for Q1 2024 and hold webcast
03/4/202422:05GLOBEQIAGEN strengthens its portfolio for cancer research,..
25/3/202421:05GLOBEQIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test..
18/3/202421:05GLOBEQIAGEN partners with International Panel Physicians..
11/3/202410:59GLOBEQIAGEN announces Form 20-F annual report filing for 2023..
27/2/202423:44GLOBEQIAGEN launches AI-derived biomedical knowledge base to..
27/2/202422:05GLOBEQIAGEN earns ACT Label for new eco-friendlier QIAwave..
15/2/202422:05GLOBEQIAGEN earns ACT Label for new eco-friendlier QIAwave..
08/2/202415:47EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/2/202422:05GLOBEQIAGEN exceeds outlook for Q4 2023, led by 8% CER sales..
25/1/202416:00GLOBEQIAGEN announces partnership with Penn State University to..
23/1/202422:13EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
18/1/202422:05GLOBEQIAGEN announces details for completion of synthetic share..
11/1/202413:53GLOBEQIAGEN N.V. to release results for Q4 2023 and hold webcast
08/1/202415:59EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/1/202408:00GLOBEQIAGEN receives FDA clearance of NeuMoDx CT/NG Assay for use..
07/1/202419:07GLOBEQIAGEN announces plans to return approximately $300 million..
04/1/202422:05GLOBEQIAGEN to accelerate investments into QIAGEN Digital..
03/1/202408:00GLOBEQIAGEN expands business in Middle East with new regional..
30/11/202322:05GLOBEDNA Labs International solves significant cold cases with..
15/11/202322:05GLOBEQIAGEN launches TissueLyser III and RNeasy PowerMax Soil Pro..
09/11/202322:05GLOBEQIAGEN launches new QIAcuity digital PCR kits and updated..
06/11/202322:05GLOBEQIAGEN launches complete Sample to Insight workflow for..
02/11/202313:00PRNUSQIAGEN and Element Biosciences partner to offer complete..
30/10/202321:05GLOBEQIAGEN exceeds outlook for Q3 2023 with 5% CER sales growth..
26/10/202314:00GLOBEQIAGEN and Myriad Genetics partner to advance companion..
09/10/202317:14GLOBEQIAGEN N.V. to release results for Q3 2023 and hold webcast
04/10/202322:05GLOBEQIAGEN launches QuantiFERON-EBV RUO assay, facilitating..
28/9/202322:05GLOBEQIAGEN extends AI capabilities of its NGS interpretation..
27/9/202322:05GLOBEQIAGEN reports progress toward achieving Environmental,..
25/9/202322:05GLOBEQIAGEN enhances QIAwave portfolio with new eco-friendlier..
25/8/202322:48EDGAR2Form 144 - Report of proposed sale of securities
10/8/202303:55EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/8/202303:40EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/8/202322:05GLOBEQIAGEN delivers ahead of outlook for Q2 2023 with 9% CER..
07/8/202322:05GLOBEQIAGEN receives FDA approval for companion diagnostic to..
26/7/202322:15GLOBEBio-Rad and QIAGEN announce patent settlement and..
24/7/202313:41GLOBEQIAGEN N.V. to release results for Q2 2023 and hold webcast
18/7/202322:05GLOBEQIAGEN expands range of digital PCR kits and services for..
20/6/202322:05GLOBEFBI approves QIAGEN’s NGS-based ForenSeq MainstAY workflow..
16/6/202313:36GLOBEQIAGEN provides reminder on settlement mechanics of 2023 and..
15/6/202322:05GLOBEQIAGEN’s QuantiFERON-TB Gold Plus shows unique clinical..
13/6/202322:05GLOBEDanish National Genome Center selects QIAGEN for variant..
03/5/202322:05GLOBEQIAGEN exceeds outlook for Q1 2023 with 12% CER sales growth..
03/5/202311:30GLOBEQIAGEN welcomes U.S. Preventive Services Task Force..
Apertura: 41,10 Min: 41,06 Max: 41,68
Chiusura: 41,08

La tua Cronologia

NYSE
QGEN
Qiagen NV
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network